ข่าวประชาสัมพันธ์ Type 2 Diabetes+hypoglycaemia

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 [NovoMix(R) 30]). The trial results were presented today at the International Diabetes Federation Congress 2017 (IDF 2017).[1] "Millions of people with type 2 diabetes participate in Ramadan every year and we know

07 ธันวาคม 2560 15:45 น.

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia... ก.ย. 60

Ryzodeg(R) Delivers Significantly Lower Rates of Hypoglycaemia and Nocturnal Hypoglycaemia in a Broad Range of Type 2 Diabetes Patients

- This material is intended for global medical media only. - This material is not approved for Canadian journalists or Canadian audiences. - For journalistic... ธ.ค. 58

Type 2 Diabetes Patients with Long-Standing Disease Achieved Glycaemic Control When BYETTA(R) (exenatide) Injection Was Added to Insulin Glargine

Study Presented at ADA 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double... มิ.ย. 53

Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers... ต.ค. 61

International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

- Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] -... ก.ย. 61

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack,... ส.ค. 61

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

- Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin... ธ.ค. 60

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1... ธ.ค. 60

Xultophy(R) Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy(R) (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus... ธ.ค. 60

Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

New findings from an indirect comparison between Xultophy(R) and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy(R) (insulin degludec... ธ.ค. 60

Merck and International Diabetes Federation Partner to Help Address Global Type 2 Diabetes Epidemic

The information contained in this release is not appropriate for audiences in the USA and Canada Focus on education and awareness-raising initiatives to facilitate prevention of type 2 diabetes... พ.ย. 60

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) Globally,... ก.ย. 60

Ascensia Diabetes Care Launches Global Innovation Competition to Find Digital Solutions to Help Tackle the Epidemic of Type 2 Diabetes

Today, during the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Ascensia Diabetes Care announced the launch of the Ascensia... ก.ย. 60

Xultophy(R) Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Oral Presentation 113 In people with type 2 diabetes, Xultophy(R) (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to... ก.ย. 60

Victoza(R) Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza(R) (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2... ส.ค. 60

Merck's Glucophage(R) SR Receives Label Extension for Patients at High Risk of Type 2 Diabetes in the UK

Not intended for U.S. based media Glucophage(R) SR offers UK healthcare professionals the first licensed treatment option for overweight adult patients at high risk of progression to type 2... พ.ค. 60

CHMP Adopts Positive Opinion of Metformin, Including Merck's Type 2 Diabetes Treatment Portfolio, in Patients with Renal Impairment

Not intended for U.S. and UK-based media Metformin receives positive CHMP opinion for treatment of type 2 diabetes patients with moderate renal impairment (CKD stage 3),... ต.ค. 59

Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes

This material is intended for global medical media only. For journalistic assessment and preparation before publication.... มิ.ย. 59

Semaglutide Demonstrated Superior Glycaemic Control vs Insulin Glargine U100 in Adults with Type 2 Diabetes

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #290 Findings from a phase 3a clinical trial for semaglutide,... พ.ค. 59

Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type 2 Diabetes

For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #OR15-1 Findings from the first phase 3a clinical trial for semaglutide, an... เม.ย. 59

Victoza(R) (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment

For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #689-P Findings from a clinical trial comparing Victoza... เม.ย. 59

Type 2 Diabetes: Patients Reporting Better Quality of Communication by their Physician Show Improved Self-care

- 'Encouraging' and 'collaborative' physician communication is linked to better patient outcomes - New IntroDia(TM) Survey patient data are presented at American Diabetes Association's(R) ... มิ.ย. 58

New Study With Victoza(R) (Liraglutide) Showed Improvements in Blood Glucose Control in Adults With Type 2 Diabetes Who Fasted During Ramadan

This material is intended for medical non-UK media only. For journalistic assessment and preparation before publication Abstract #1121-P New findings showed... มิ.ย. 58

European Commission Approves Trulicity(R) (dulaglutide) Solution for Injection, Lilly's Once-Weekly, Ready-to-Use Type 2 Diabetes Treatment

Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle... พ.ย. 57